Final-Program-ATS-2023-AP.vp

SUNDAY • MAY 21

53

210 Topology-based Machine Learning Identifies New High-risk Phenotype of Pulmonary Arterial Hypertension Defined by Echocardiographic Parameters/ A. Alexander, Bryan, TX 211 Comparative Effective Analysis of Treatment for Pulmonary Arterial Hypertension: An Individual Participant Data Network Meta-analysis/ J. Moutchia, Philadelphia, PA 212 Stressed Blood Volume Changes in a Cohort of Patients With Preload Insufficiency/ S. Fakhri, Pittsburgh, PA 213 Clinical Characteristics of Pulmonary Embolism Identified by Electrical Impedance Tomography in Patients With Suspected Chronic Thromboembolic Pulmonary Hypertension/ X. Wu, Shanghai, China 214 Metabolomic Assessment of Preload Insufficiency Compared to Preload Insufficiency Controls During Rest and Peak Exercise/ M.G. Risbano, Pittsburgh, PA

925 Genome Filtering Based on Wood Smoke-Responsive Enhancer RNA Transcription Identifies Novel Functional Genetic Variants Associated With Asthma Risk/ A. Gupta, Denver, CO

BASIC • CLINICAL • TRANSLATIONAL RAPID: RAPID ABSTRACT POSTER DISCUSSION SESSION

A26

PRECISION-BASED APPROACHES TO PULMONARY VASCULAR DISEASE

9:00 a.m. - 11:00 a.m.

Walter E. Washington Convention Center Room 103 A-B (Street Level)

Viewing

9:00-9:45 9:45-11:00

Summaries/Discussion

Chairing: B. Maron, MD, Boston, MA

S. Provencher, MD, Quebec City, Canada A. Hemnes, MD, ATSF, Nashville, TN 201 The Role of Long-Term Daily Activity Monitoring for the Assessment of Functional Capacity in Pulmonary Arterial Hypertension/ A. Hughes, Nashville, TN 202 Heterogeneity of Treatment Effects by Predicted Risk in Pulmonary Arterial Hypertension: An Individual Participant Data Meta-analysis/ H.-M. Pan, Philadelphia, PA 203 Epicardial Adipose Tissue Is Associated With Worse Survival in Pulmonary Arterial Hypertension/ B.E. Mccarthy, Philadelphia, PA 204 Sex Differences in the Baseline Phenotype of Chronic Thromboembolic Pulmonary Hypertension Patients in the United States CTEPH Registry/ M.M. Cirulis, Salt Lake City, UT 205 Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)/ E. Bajwa, Rahway, NJ 206 Prognostic Implications of New Definitions of Pulmonary Hypertension at 5,280 Feet/ A. Longino, Aurora, CO 207 AI-based Clot Burden Detection and Assessment for CTEPH Severity/ P. Nardelli, Boston, MA 208 Medication Non-adherence and Health-related Outcomes in Patients With Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR)/ E.W. Robbins, Providence, RI 209 Administration of KER-012, a Modified Activin Receptor

BASIC • CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION

A27

WHITE PLAGUE (TUBERCULOSIS) RESEARCH

9:00 a.m. - 11:00 a.m.

Marriott Marquis Washington Marquis Ballroom, Salons 9-10 (Level M2)

Poster Viewing

9:00-9:45 9:45-11:00

Discussion

Chairing: M. Farhat, MD, Boston, MA

M. Campo Patino, MD, Minneapolis, MN P. Escalante, MD, MSc, Rochester, MN 1001 The Long-term Impact of Early-life Tuberculosis Disease on Child Health: A Prospective Birth Cohort Study/ L. Martinez, Boston, MA 1002 Admissions Due to Childhood Tuberculosis at Two Referral Hospitals in Uganda/ G.L. Becker, Iowa City, IA 1003 Use of a Digital Adherence Technology for TB Treatment Supervision in Adolescents/ A. Schraufnagel, San Francisco, CA 1004 The Impact Study: A Cluster-randomised Clinical and Health Economic Feasibility Study of a Theory-based Manualised Intervention to Support People With Tuberculosis Disease During Treatment/ M.C.I. Lipman, London, United Kingdom 1005 Impact of COVID-19 Pandemic on the Public-private Mix Tuberculosis Control Project in Korea: Analysis of the Monitoring Indicators Before and During COVID-19 Pandemic/ J.S. Park, Cheonan, Korea, Republic of

IIB Ligand Trap, Led to Changes in Biomarkers of Cardiovascular Health in a Ph1 Study Conducted in Healthy Post-Menopausal Women/ H. Natarajan, Lexington, MA

ATS 2023 • Washington, DC